Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory? by Cheson, B.D

Get full text

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes by Pfeifer, M, Zheng, B, Erdmann, T, Koeppen, H, McCord, R, Grau, M, Staiger, A, Chai, A, Sandmann, T, Madle, H, Dörken, B, Chu, Y-W, Chen, A I, Lebovic, D, Salles, G A, Czuczman, M S, Palanca-Wessels, M C, Press, O W, Advani, R, Morschhauser, F, Cheson, B D, Lenz, P, Ott, G, Polson, A G, Mundt, K E, Lenz, G

Get full text

Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia by Ghia, P, Coutre, S.E, Furman, R.R, Sharman, J.P, Cheson, B.D, Pagel, J.M, Hillmen, P, Barrientos, J.C, Zelenetz, A.D, Kipps, T.J, Flinn, I.W, Eradat, H.A, Lamanna, N, Coiffier, B, Pettitt, A, Li, X, Jahn, T.M, O'Brien, S.M, Hallek, M.J

Get full text

PHASE IB/II STUDY OF IBRUTINIB AND VENETOCLAX IN RELAPSED AND REFRACTORY FOLLICULAR LYMPHOMA by Ujjani, C., Wang, H., Leslie, L., Johnson, M., Cheson, B.D.

Get full text

Internal and external validation of THROLY (thrombosis lymphoma) score by Antic, D., Biljana, M., Milic, N., Cheson, B.D., Narkhede, M., Panovska, I., Trajkova, S., Popova, M., Llamas, P., Raso, A.G., Delluc, A., Ianotto, J.C., Gerotziafas, G.T., Fareed, J.

Get full text

PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA by Rogers, K.A., Thompson, P.A., Allan, J.N., Coleman, M., Sharman, J.P., Cheson, B.D., Izumi, R., Frigault, M.M., Quah, C., Raman, R.K., Wang, M.H., Kipps, T.J.

Get full text

HYPERTENSION (HTN) IN PATIENTS (PTS) TREATED WITH IBRUTINIB (IBR) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) by Sarraf Yazdy, M., Roeker, L., Gashonia, L., Goodfriend, J., Narkhede, M., Rhodes, J., Kennard, K., Morse, H., Dorsey, C., Battiato, K., Deonarine, I., Carver, J., Schuster, S.J., Cheson, B.D., Mato, A.

Get full text

6003 ORAL Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL) by Crump, M, Coiffier, B, Jacobsen, E.D, Sun, L, Ricker, J.L, Xie, H, Frankel, S.R, Randolph, S.S, Cheson, B.D

Get full text

PS1151 PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA by Rogers, K., Thompson, P.A., Allan, J.N., Coleman, M., Sharman, J.P., Cheson, B.D., Izumi, R., Frigualt, M.M., Quah, C., Raman, R.K., Wang, M.H., Kipps, T.J.

Request full text

A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY by Mato, A.R., Schuster, S.J., Lamanna, N., Pagel, J.M., Flinn, I.W., Barrientos, J., Reeves, J.A., Cheson, B.D., Barr, P.M., Kambhampati, S., Lansigan, F., Pu, J.J., Skarbnik, A., Fonseca, G., Dorsey, C., LaRatta, N.M., Weissbrot, H., Svoboda, J., Luning Prak, E.T., Tsao, P., Sitlinger, A., Paskalis, D., Sportelli, P., Miskin, H.P., Weiss, M.S., Brander, D.M.

Get full text

FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA by Martin, P., Jung, S., Pitcher, B., Bartlett, N.L., Blum, K.A., Shea, T., Ruan, J., Smith, S.E., Leonard, J.P., Cheson, B.D.

Get full text

MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE by Pott, C., Belada, D., Danesi, N., Fingerle‐Rowson, G.R., Gribben, J., Harbron, C.G., Hoster, E., Kahl, B.S., Kehden, B., Mundt, K.E., Nicolas‐Virelizier, E., Sehn, L.H., Cheson, B.D.

Get full text